Solid Biosciences Inc. (SLDB) compared with its closest peers (INBX, MGTX, VOR, ODTX, SANA). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | $1.46B | -8.7 |
| MeiraGTx Holdings plc (MGTX) | $1.39B | 79.3 |
| Vor Biopharma Inc. (VOR) | $1.25B | -0.2 |
| Odyssey Therapeutics, Inc. (ODTX) | $1.19B | — |
| Sana Biotechnology, Inc. (SANA) | $1.12B | -4.2 |
| Candel Therapeutics, Inc. (CADL) | $944.24M | -7.8 |
| 4D Molecular Therapeutics, Inc. (FDMT) | $887.29M | -3.1 |
| Aura Biosciences, Inc. (AURA) | $804.23M | -3.1 |
| Allogene Therapeutics, Inc. (ALLO) | $721.37M | -1.6 |
| Tectonic Therapeutic, Inc. (TECX) | $678.35M | -5.1 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
SLDB overview · SLDB earnings · SLDB financials · SLDB KPIs · SLDB investor relations · SLDB ownership · SLDB filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.